HS
IOVA icon

HighVista Strategies’s Iovance Biotherapeutics IOVA Stock Holding History

HighVista Strategies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-66,526
Closed -$468K – 150
2023
Q2 		$468K Buy
+66,526
New +$476K 0.21% 120
2022
Q4 		– Sell
-72,104
Closed -$691K – 114
2022
Q3 		$691K Buy
72,104
+27,142
+60% +$313K 0.39% 70
2022
Q2 		$496K Sell
44,962
-9,439
-17% -$124K 0.3% 76
2022
Q1 		$906K Sell
54,401
-12,238
-18% -$189K 0.58% 44
2021
Q4 		$1.27M Buy
66,639
+10,363
+18% +$228K 1.01% 31
2021
Q3 		$1.39M Buy
56,276
+23,818
+73% +$561K 0.92% 23
2021
Q2 		$845K Buy
32,458
+14,295
+79% +$372K 0.6% 35
2021
Q1 		$575K Sell
18,163
-2,260
-11% -$93.7K 0.43% 63
2020
Q4 		$948K Buy
20,423
+3,599
+21% +$143K 0.61% 31
2020
Q3 		$554K Buy
16,824
+1,343
+9% +$41.2K 0.4% 38
2020
Q2 		$425K Buy
+15,481
New +$509K 0.35% 45

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighVista Strategies's IOVA Position: Q3 2023 in Review

HighVista Strategies sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 66,526 shares — an estimated $468K sold.

HighVista Strategies first reported a position in IOVA in Q2 2020 and held it in 11 quarters. The position peaked at $1.39M in Q3 2021. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

  • HighVista Strategies reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • HighVista Strategies sold 66,526 Iovance Biotherapeutics shares in Q3 2023, an estimated $468K.
  • HighVista Strategies first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 11 quarters.
  • HighVista Strategies's Iovance Biotherapeutics position peaked at $1.39M in Q3 2021.
  • 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.